AMGEN-AMG-509-20230237
Phase I
OPEN TO ACCRUAL
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects with Newly Diagnosed Localized Intermediate or High-risk Prostate Cancer
NRG-GU010-GUIDANCE
Phase III
OPEN TO ACCRUAL
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)